| scholarly article | Q13442814 |
| P2093 | author name string | Charles P Semba | |
| Eric D Donnenfeld | |||
| Parag A Majmudar | |||
| Aparna Raychaudhuri | |||
| Kelly K Nichols | |||
| Paul M Karpecki | |||
| Monica Roy | |||
| P2860 | cites work | A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye | Q83435570 |
| Molecular mechanisms of T cell co-stimulation and co-inhibition | Q26864888 | ||
| The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs | Q34165372 | ||
| Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study | Q34493904 | ||
| The role of the integrin LFA-1 in T-lymphocyte migration | Q36877329 | ||
| Role of the tear film in the optical quality of the human eye. | Q36919382 | ||
| Etiology, prevalence, and treatment of dry eye disease | Q37288773 | ||
| Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. | Q39730888 | ||
| Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118) | Q40356553 | ||
| Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration | Q40543299 | ||
| Mechanisms of inflammation and leukocyte activation | Q41333486 | ||
| Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study | Q42708147 | ||
| ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice | Q44809776 | ||
| Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. | Q45950875 | ||
| LFA-1: more than just T cell Velcro | Q79227639 | ||
| Noninvasive, objective, multimodal tear dynamics evaluation of 5 over-the-counter tear drops in a randomized controlled trial | Q82791873 | ||
| P433 | issue | 6 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| placebo | Q269829 | ||
| eye disease | Q3041498 | ||
| lifitegrast | Q23044263 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 741-748 | |
| P577 | publication date | 2016-04-06 | |
| P1433 | published in | Cornea | Q15760110 |
| P1476 | title | Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | |
| P478 | volume | 35 |
| Q64226436 | A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease |
| Q92442286 | Advances in dry eye disease treatment |
| Q48095233 | Current Anti-Integrin Therapy for Ocular Disease |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q26746232 | Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease |
| Q39404635 | Dry Eye Management: Targeting the Ocular Surface Microenvironment. |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q36252489 | Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment |
| Q39025675 | LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease |
| Q39069560 | Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease |
| Q59794055 | Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report |
| Q45037685 | Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials |
| Q38608475 | Lifitegrast for the treatment of dry eye disease in adults |
| Q33739879 | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| Q37591609 | Lifitegrast: A novel drug for treatment of dry eye disease |
| Q93137705 | Lifitegrast: a novel drug for patients with dry eye disease |
| Q64106425 | Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity |
| Q89536542 | Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies |
| Q91935784 | Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease |
| Q47268214 | Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs |
| Q49261503 | Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. |
| Q58694745 | Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort |
| Q92236526 | Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review |
| Q90351231 | The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options |
| Q90418082 | The efficacy and safety of qiming granule in dry eye disease: Protocol for systematic review and meta-analysis |
| Q50110517 | Therapeutic inhibitors for the treatment of dry eye syndrome. |
| Q91632324 | Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease |
| Q47620917 | Update on the Management of High-Risk Penetrating Keratoplasty |
| Q50039889 | [Novel current and future therapy options for treatment of dry eye disease]. |
Search more.